ANNX News and Press, Annexon Inc. From 11/12/25

BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has commenced a...

2025-11-10 16:56:38 ET More on Annexon Biosciences Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript Annexon, Inc. (ANNX) Presents at Cantor Global Healthcare Conference 2025 Transcript Seeking Alpha’s Quant Rating ...

Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome ( GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA Filing in January 2026; Potential to Be the First Approved Targeted and Fast-Acting T...

2025-09-29 14:00:34 ET The Pharmaceuticals sector is seeing the largest upward movement on the PRISM MarketView Index today, rising 2.1%. This outperformance is driven by a standout gain in Applied Therapeutics ( APLT ), which has surged over 121% , reflecting strong investor intere...

2025-09-07 21:58:20 ET Annexon, Inc. (ANNX) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 3:00 PM EDT... Read the full article on Seeking Alpha For further details see: Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025...

2025-09-05 01:38:20 ET Annexon, Inc. (ANNX) Cantor Global Healthcare Conference 2025 September 4, 2025 8:00 AM EDT... Read the full article on Seeking Alpha For further details see: Annexon, Inc. (ANNX) Presents at Cantor Global Healthcare Conference 2025 Transcript

2025-08-14 17:18:32 ET More on Annexon Biosciences Annexon: Lead GBS Therapy Stokes Near-Term Potential Seeking Alpha’s Quant Rating on Annexon Biosciences Historical earnings data for Annexon Biosciences Financial information for Annexon Biosciences ...

Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA Accelerated Completion of Enrollment for Global Phase 3 ARC...

Xenon Pharmaceuticals Inc. (XENE) is expected to report $-1.03 for Q2 2025 Gaia Inc. (GAIA) is expected to report $-0.08 for Q2 2025 Insight Molecular Diagnostics Inc. (IMDX) is expected to report for Q2 2025 Lightbridge Corporation (LTBR) is expected to report for Q2 2025 NewHold...

Annexon Inc. (ANNX) is expected to report $-0.36 for Q2 2025